Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Everolimus also shows antiangiogenic/vascular effects in VEGF-induced HUVEC proliferation with IC50 of 0
CAS Number: 2102933-95-7
with EC50 values of 0
Smiles: COC1=CC2=NC=NC(NC3=CC(Cl)=C(F)C=C3)=C2C=C1O
Prasugrel - CAS# 150322-43-3 lupirtine Maleate Everolimus also shows antiangiogenic/vascular effectsPrasugrel (marketing name Effient in the US, Efient in the EU and Prasita in India) is a novel platelet inhibitor developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). Prasugrel was approved for use in Europe in February 2009, and is currently available in the UK. On July 10, 2009, the
US$ 48.00
US$ 36.00
US$ 25.00
US$ 138.00